Daniel Howard

Icelandic biotech Alvotech seeks $125M in a complex dual offering to advance its low-cost drug pipeline, but regulatory hurdles and financial pressures loom.

With a new critical illness feature, AuguStar Life is challenging the insurance industry's opaque benefit models with a clear, predictable lien system.

A new study offers hope for MS by promoting nerve repair, but the real story is the validation of a versatile stem cell platform for a new era of medicine.

With a critical 2026 deadline looming, only 1% of defense contractors are ready for new cyber rules. One IT provider's flawless audit offers a new path.

In a year with the fewest home sales since 2007, one Nevada real estate team didn't just survive; it dominated. Here's how they did it.

Padel is exploding across North America, but its growth depends on quality infrastructure. A new partnership marries local manufacturing with global tech.

The Shanghai Museum dedicates its entire venue to 3,000 artifacts from Mexico and Peru. This isn't just an exhibition; it's a new model for cultural infrastructure.

A landmark 5GWh agreement between Fox ESS and OSW isn't just about storage; it’s a blueprint for a decentralized, resilient, and renewable-powered grid.

A landmark deal for CEL-SCI’s cancer drug Multikine in Saudi Arabia isn't just about a new market; it’s a case study in national ambition and biotech finance.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

By upgrading to the OTCQX market, junior explorer Tesoro Gold isn't just changing its ticker; it's tapping a vital financial system to fund a massive Chilean gold project.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

With a record-breaking IPO and over $1.2 billion raised this year, Parabilis Medicines is attacking diseases once thought untouchable. But can its Helicon platform deliver?

Methodist Healthcare Ministries is building Ministry Park, a 16-acre development that combines affordable patient lodging with public green space, pioneering a new model for social impact.

Andersen Consulting partners with HeadMind Partners, leveraging deep European expertise in cybersecurity and AI to bolster its global transformation services.

Rugs.com's new app uses augmented reality to solve online shopping's biggest challenge: uncertainty. It's a look into the new baseline for digital retail.

A major funding round positions GPS Renewables to accelerate India's transition to cleaner fuels, turning waste into a cornerstone of national energy security.

With shareholder backing and a major acquisition nearly complete, IsoEnergy is building a global uranium powerhouse to meet soaring nuclear energy demand.

A new report reveals generative AI is ignoring decade-long SEO winners like Chegg, favoring brands like Khan Academy. The lesson? Authority is the new algorithm.